At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.
GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog.
The BEACON-IPF Phase 2b trial, which was assessing bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), has been discontinued by Pliant Therapeutics, Inc. after a [Read More…]
Two blockbuster weight loss drugs including Lilly’s Zepbound were in U.S. FDA’s drugs shortage list.
The European Commission is currently taking final action on the application for the use of Jaypirca in patients with relapsed or refractory CLL who have received prior treatment with a BTK inhibitor as a result of this favorable view.
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the [Read More…]
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
A study team headed by Gernot Längst (University of Regensburg) and Markus Meißner (LMU Munich) has made significant progress in understanding the gene regulation of the malaria pathogen.
